Ascend Advanced Therapies has placed a multi-million dollar investment into supporting its global infrastructure.
This includes the expansion of its GMP suite capacity up to 500L, as well as the addition of fill finish capacity at its Alachua, Florida site.
At its Munich facility, Ascend is also in the process of boosting its GMP quality control testing, analytical and process development services, which will allow it to meet industry demand on a global scale.
These expansions will likely run into 2025.
Ascend's Alachua site will now feature novel manufacturing suites and fill/finish capabilities, with additional space being allocated to build out temperature-controlled GMP warehousing and process development labs.
CEO of Ascend, Mike Stella, commented: “There are both tangible and intangible assets that make a company want to work with a contract manufacturer. Our goal is to align these assets and deliver clients an exceptional experience, regardless of whether it is development projects or full clinical drug production,”
“As our footprint grows, we will iterate over 2 decades of therapeutic AAV expertise into a connected global footprint with cutting-edge, enabling technologies, and analytics for our clients.”
Since inception, Ascend has differentiated the business with specialised gene therapy support for developers combining a small entrepreneurial, collaborative culture with an exceptional technology portfolio.
